The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Tackle Tricky Lung Complications in Connective Tissue Disease

Tackle Tricky Lung Complications in Connective Tissue Disease

February 15, 2013 • By Susan Bernstein

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Diagnosis typically involves assessing pulmonary function and examining high-resolution computed tomography (HRCT) scans. Bronchoscopy also may be a useful diagnostic tool, along with bronchoalveolar lavage to assess for infection and alveolar hemorrhage, Dr. Fischer said. Transbronchial biopsy may not add much useful information, he added.

You Might Also Like
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • Summit on Connective Tissue Disease-Associated ILD Fosters Interdisciplinary Dialogue
Also By This Author
  • 2019 EULAR/ACR SLE Classification Criteria Offer Improved Sensitivity & Specificity

It’s important for pulmonologists to get rheumatologists involved in diagnosis and treatment for these patients, Dr. Fischer said. ILD has a “rheumatologic flavor,” he said, with some patients presenting with specific autoantibodies and histopathologic features. With connective tissue–associated ILD, however, there often is a lack of extrathoracic features, he said.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

How should these conditions be treated? For ILD in systemic sclerosis (SSc-ILD), the rheumatologist must first ask whom to treat, when to treat, and what therapy to try, said Richard Silver, MD, professor of medicine and pediatrics at the Medical University of South Carolina in Charleston.

Severity of SSc-ILD is greater in African Americans, males, and patients over age 70, Dr. Silver said. Risk factors include patients who are positive for the Scl-70 or U11/U12 RNP antibody and patients with severe esophageal disease, he said. “We have to look at patients phenotypically, seriologically, and, in the future, genotypically as well, to identify patients who are at the highest risk” of developing ILD, he added.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the future, rheumatologists may be able to identify who is at higher risk for ILD and target those people for more aggressive therapy, Dr. Silver said. Serum biomarkers for SSc-ILD include SP-D and KL-6. Patients who had both SSc and alveolitis by bronchoalveolar lavage or ground glass on HRCT chest scan had higher serum levels of both SP-D and KL-6, a potentially prognostic factor in the decline of lung function in these patients, he added.

Targeting Treatment

When should rheumatologists observe and wait to treat patients, and when should they intervene immediately? HRCT results showing the extent of ground glass opacity and forced vital capacity (FVC) levels are two key determinants, Dr. Silver noted. For example, if FVC is greater than or equal to 70% predicted, it may be best to observe and delay treatment. If FVC is less than 70% and lung function is declining, treatment may be warranted.

Cyclophosphamide is an effective treatment, but toxicity concerns make long-term use problematic, Dr. Silver said. Other treatments now in clinical trials are mycophenolate mofetil, imatinib mesylate, and rituximab. In the future, treatments like immunosuppressive therapy, antifibrotic therapy, or cell-based therapy with hematopoietic or mesenchymal stem cells may help these patients, he said. Biomarker research may soon offer more useful clues for treatment options, Dr. Silver said. “At this point, it is the art and not the science of medications,” he concluded.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Scleroderma Tagged With: connective tissue disease, Interstitial Lung Disease, Systemic sclerosis

You Might Also Like:
  • When Interstitial Lung Disease and Connective Tissue Disorder Intersect in Rheumatology Patients
  • Cyclophosphamide for Connective Tissue Disease-Associated Interstitial Lung Disease
  • Summit on Connective Tissue Disease-Associated ILD Fosters Interdisciplinary Dialogue
  • The ACR’s State-of-the-Art Clinical Symposium: Patients with Scleroderma, Lung Disease May Benefit from Aggressive Therapy

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.